This invention relates to a device for delivering medication to the nasal cavity of a human patient.
Devices which deliver medication to the nasal cavities are known. In some cases they create an aerosol from liquid medication using compressed gas or piezoelectric energy. They are often referred to as “nebulisers” and they typically have a chamber in which the medication is energised. The medicament is then caused to contact a mesh, or to move through a jet nozzle, to enter the nasal cavities as an aerosol. The mesh may be vibrated directly via a piezo-oscillating element, or indirectly as a result of acoustic energy. The acoustic energy may also be used to drive the medication to the mesh.
Some nebulisers have a drawback in that their delivery mechanism requires an undesirably large minimum volume of medication before they can do their work. When the medication falls to below that volume a relatively large residual amount is wasted. It is an object of a preferred embodiment of the present invention to go at least some way towards alleviating this problem. However this and any other objects of the preferred embodiment should not be taken as a limitation on the scope of the invention or claims. The object of the invention in its broadest form is simply to provide a useful choice.
According to one aspect of the invention there is provided a delivery device for nasal medication, having:
Optionally the device has a mouthpiece adapted for a human user to blow into and sensing means which, in response to such blowing, causes the medication to be energised and the aerosol to form.
Optionally the energising chamber has a volume of 0.1 cm3 to 0.8 cm3, and preferably a volume of 0.2 cm3 to 0.4 cm3.
Optionally the ultrasonic generator comprises a concave transducer adapted to focus ultrasonic energy on the focal zone when activated, such that the medication in the energising chamber becomes acoustically energised and moves towards the mesh.
Optionally the device is formed such that it causes the mesh to vibrate as the medication contacts it so as to assist in creating the aerosol.
Optionally the device has a nasal prong and the exit is part of the prong.
Optionally the mesh is integral with the prong.
Optionally the mesh is immediately adjacent to the exit so as to prevent or minimise condensation of the aerosol inside the device.
Optionally the energising chamber, the generator and exit are at an angle of about 40° to about 80°, and preferably about 50° to about 70°, with respect to the mouthpiece.
Optionally the medication is a pharmaceutical or saline solution prior to being energised.
Optionally the feeder chamber has a funnel or flume formed to naturally encourage the medication into the energising chamber.
Optionally the energising chamber has a tapered floor to urge medication to gather at the focal zone.
Optionally the energising chamber has a well to urge medication to gather at the focal zone.
Optionally the energising chamber is symmetrical.
Optionally the energising chamber is asymmetrical.
Optionally the feeder chamber plus the energising chamber collectively have sufficient medication for:
According to a further aspect f the invention there is provided a delivery device for nasal medication, having:
Some preferred embodiments of the invention will now be described by way of example and with reference to the accompanying drawings, of which:
Referring to
The Main Body
The main body 1 has an LCD screen 4 to display messages to the user, for example the name of the medicine to be delivered, the time at which the next dose is due to be taken, etc. The main body 1 also has a battery, a USB port 5 for charging the battery or for receiving input generally, an on/off power switch 6, an RFID reader 7 and a breath sensor. All of the electronics for the delivery device are part of the main body 1.
The RFID reader 7 is able to read electronically stored prescription details kept on a tag on the medicine packaging. Those details are used to automatically set the device to deliver the prescribed amount of medicine.
The Breath Receptor
The breath receptor 2 is detachable from the main body 1 with a click-fit arrangement, and has a detachable replaceable mouthpiece 8. The mouthpiece 8 can be gripped between the lips of the user and blown into. As the breath moves through the receptor 2 it is acoustically detected by the sensor in the main body 1, and, as a consequence, the device is triggered to deliver medicine to the user. The breath then passes out the back 9 of the device, having served its purpose. The device only releases medicine while the user is blowing/exhaling. This is because the act of exhaling causes the user's pharynx to close, so that medicine is only delivered to the nose, and not the throat or lungs.
The Medicine Supply Unit
Referring to
With particular reference to
With further reference to
In the preferred embodiment the energising chamber 14 is approximately 0.2 cm3 to 0.4 cm3 in size. The small size of the energising chamber 14 with respect to the liquid storage chamber 13 means that the size of the focal zone 19 is minimised. This helps to minimise or substantially limit the amount of residual medicine (wastage) in the energising chamber 14 when the feeder chamber is exhausted.
The liquid medicine 18a in the energising chamber 14 is replenished with a new charge of medicine 18b under normal gravity from the feeder chamber 13. This ensures that there is always a charge of medicine 18a ready to be acoustically energized, that is until the medicine in the liquid storage chamber is emptied. When there is insufficient volume of medicine in the energising chamber 14 there will not be enough acoustic radiation pressure to effectively oscillate the mesh 15.
Referring to
Referring to
Other Features
In some embodiments of the invention the device will only run if the user has purchased sufficient electronic ‘credits’, which are communicated to the device wirelessly or by hardwire.
Referring to
While some preferred forms of the invention have been described by way of example, it should be appreciated that modifications and improvements can occur without departing from the scope of the following claims.
Number | Date | Country | Kind |
---|---|---|---|
706864 | Apr 2015 | NZ | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/NZ2016/050002 | 1/8/2016 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2016/163895 | 10/13/2016 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3387607 | Gauthier | Jun 1968 | A |
6705312 | Tanaka | Mar 2004 | B2 |
7347201 | Djupesland | Mar 2008 | B2 |
7426866 | Van Tuyl | Sep 2008 | B2 |
7721729 | Von Hollen | May 2010 | B2 |
20060201502 | Lieberman | Sep 2006 | A1 |
20060243274 | Lieberman | Nov 2006 | A1 |
20080022395 | Holtzman | Jan 2008 | A1 |
20080156320 | Low | Jul 2008 | A1 |
20080223953 | Tomono | Sep 2008 | A1 |
20080245362 | Moessis | Oct 2008 | A1 |
20090200397 | Sheiman | Aug 2009 | A1 |
20100023654 | Ramsdale | Jan 2010 | A1 |
20110012045 | Schaefer et al. | Jan 2011 | A1 |
20110120456 | Immel | May 2011 | A1 |
20130112197 | Kruener et al. | May 2013 | A1 |
20140025133 | Lozano | Jan 2014 | A1 |
20140352689 | Seshadri et al. | Dec 2014 | A1 |
20160058960 | Papania | Mar 2016 | A1 |
Number | Date | Country |
---|---|---|
WO2004045690 | Jun 2004 | WO |
2007028203 | Mar 2007 | WO |
WO2013132427 | Sep 2013 | WO |
Entry |
---|
Int'l Search Report and Written Opinion for Int'l Patent App. No. PCT/NZ2016/050002, dated Apr. 15, 2016, 13 pages, Australian Patent Office, International Bureau. |
Int'l Preliminary Reporton Patentability for Int'l Patent App. No. PCT/NZ2016/050002, dated Jun. 14, 2017, 19 pages, Australian Patent Office, International Bureau. |
Number | Date | Country | |
---|---|---|---|
20180036498 A1 | Feb 2018 | US |